澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate, quantity: 21.75 mg - tablet, enteric coated - excipient ingredients: polysorbate 80; mannitol; hyprolose; magnesium stearate; purified water; purified talc; microcrystalline cellulose; triethyl citrate; propylene glycol; methacrylic acid - ethyl acrylate copolymer (1:1); colloidal anhydrous silica; sodium lauryl sulfate; calcium hydrogen phosphate dihydrate; self-emulsifying glyceryl monostearate; crospovidone; hypromellose; titanium dioxide; maltodextrin; iron oxide yellow; iron oxide red; polydextrose; medium chain triglycerides - gastro-oesophageal reflux disease (gord) ,? treatment of erosive reflux oesophagitis ,? long-term management of patients with healed oesophagitis to prevent relapse ,? symptomatic treatment of gastro-oesophageal reflux disease (gord) ,? patients requiring nsaid therapy ,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ,? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug ,nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. ,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion ,in combination with appropriate antibiotics for: ,? healing of duodenal ulcer associated with helicobacter pylori ,? eradication of helicobacter pylori in patients with active or healed peptic ulcer

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate, quantity: 43.5 mg - tablet, enteric coated - excipient ingredients: sodium lauryl sulfate; purified water; purified talc; propylene glycol; hypromellose; polysorbate 80; magnesium stearate; hyprolose; methacrylic acid - ethyl acrylate copolymer (1:1); triethyl citrate; calcium hydrogen phosphate dihydrate; mannitol; microcrystalline cellulose; crospovidone; colloidal anhydrous silica; self-emulsifying glyceryl monostearate; titanium dioxide; maltodextrin; iron oxide yellow; iron oxide red; polydextrose; medium chain triglycerides - gastro-oesophageal reflux disease (gord) ,? treatment of erosive reflux oesophagitis ,? long-term management of patients with healed oesophagitis to prevent relapse ,? symptomatic treatment of gastro-oesophageal reflux disease (gord) ,? patients requiring nsaid therapy ,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ,? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug ,nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. ,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion ,in combination with appropriate antibiotics for: ,? healing of duodenal ulcer associated with helicobacter pylori ,? eradication of helicobacter pylori in patients with active or healed peptic ulcer

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate, quantity: 21.75 mg - tablet, enteric coated - excipient ingredients: self-emulsifying glyceryl monostearate; purified water; methacrylic acid - ethyl acrylate copolymer (1:1); hyprolose; hypromellose; polysorbate 80; sodium lauryl sulfate; triethyl citrate; magnesium stearate; colloidal anhydrous silica; crospovidone; microcrystalline cellulose; propylene glycol; calcium hydrogen phosphate dihydrate; mannitol; purified talc; titanium dioxide; maltodextrin; iron oxide yellow; iron oxide red; polydextrose; medium chain triglycerides - gastro-oesophageal reflux disease (gord) ,? treatment of erosive reflux oesophagitis ,? long-term management of patients with healed oesophagitis to prevent relapse ,? symptomatic treatment of gastro-oesophageal reflux disease (gord) ,? patients requiring nsaid therapy ,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ,? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug ,nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. ,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion ,in combination with appropriate antibiotics for: ,? healing of duodenal ulcer associated with helicobacter pylori ,? eradication of helicobacter pylori in patients with active or healed peptic ulcer

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate, quantity: 21.75 mg - tablet, enteric coated - excipient ingredients: purified talc; sodium lauryl sulfate; hyprolose; purified water; methacrylic acid - ethyl acrylate copolymer (1:1); hypromellose; mannitol; microcrystalline cellulose; propylene glycol; polysorbate 80; colloidal anhydrous silica; self-emulsifying glyceryl monostearate; crospovidone; magnesium stearate; calcium hydrogen phosphate dihydrate; triethyl citrate; titanium dioxide; maltodextrin; iron oxide yellow; iron oxide red; polydextrose; medium chain triglycerides - gastro-oesophageal reflux disease (gord) ,? treatment of erosive reflux oesophagitis ,? long-term management of patients with healed oesophagitis to prevent relapse ,? symptomatic treatment of gastro-oesophageal reflux disease (gord) ,? patients requiring nsaid therapy ,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ,? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug ,nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. ,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion ,in combination with appropriate antibiotics for: ,? healing of duodenal ulcer associated with helicobacter pylori ,? eradication of helicobacter pylori in patients with active or healed peptic ulcer

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate, quantity: 43.5 mg - tablet, enteric coated - excipient ingredients: purified water; magnesium stearate; sodium lauryl sulfate; triethyl citrate; microcrystalline cellulose; hypromellose; crospovidone; methacrylic acid - ethyl acrylate copolymer (1:1); polysorbate 80; self-emulsifying glyceryl monostearate; mannitol; purified talc; propylene glycol; hyprolose; calcium hydrogen phosphate dihydrate; colloidal anhydrous silica; titanium dioxide; maltodextrin; iron oxide yellow; iron oxide red; polydextrose; medium chain triglycerides - gastro-oesophageal reflux disease (gord) ,? treatment of erosive reflux oesophagitis ,? long-term management of patients with healed oesophagitis to prevent relapse ,? symptomatic treatment of gastro-oesophageal reflux disease (gord) ,? patients requiring nsaid therapy ,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ,? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug ,nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. ,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion ,in combination with appropriate antibiotics for: ,? healing of duodenal ulcer associated with helicobacter pylori ,? eradication of helicobacter pylori in patients with active or healed peptic ulcer

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate, quantity: 43.5 mg - tablet, enteric coated - excipient ingredients: polysorbate 80; magnesium stearate; purified talc; purified water; crospovidone; self-emulsifying glyceryl monostearate; hyprolose; methacrylic acid - ethyl acrylate copolymer (1:1); hypromellose; calcium hydrogen phosphate dihydrate; sodium lauryl sulfate; triethyl citrate; mannitol; microcrystalline cellulose; propylene glycol; colloidal anhydrous silica; titanium dioxide; maltodextrin; iron oxide yellow; iron oxide red; polydextrose; medium chain triglycerides - gastro-oesophageal reflux disease (gord) ,? treatment of erosive reflux oesophagitis ,? long-term management of patients with healed oesophagitis to prevent relapse ,? symptomatic treatment of gastro-oesophageal reflux disease (gord) ,? patients requiring nsaid therapy ,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ,? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug ,nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. ,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion ,in combination with appropriate antibiotics for: ,? healing of duodenal ulcer associated with helicobacter pylori ,? eradication of helicobacter pylori in patients with active or healed peptic ulcer

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate, quantity: 21.75 mg - tablet, enteric coated - excipient ingredients: microcrystalline cellulose; triethyl citrate; magnesium stearate; colloidal anhydrous silica; polysorbate 80; purified water; calcium hydrogen phosphate dihydrate; hypromellose; mannitol; sodium lauryl sulfate; self-emulsifying glyceryl monostearate; purified talc; hyprolose; propylene glycol; crospovidone; methacrylic acid - ethyl acrylate copolymer (1:1); titanium dioxide; maltodextrin; iron oxide yellow; iron oxide red; polydextrose; medium chain triglycerides - gastro-oesophageal reflux disease (gord) ,? treatment of erosive reflux oesophagitis ,? long-term management of patients with healed oesophagitis to prevent relapse ,? symptomatic treatment of gastro-oesophageal reflux disease (gord) ,? patients requiring nsaid therapy ,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ,? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug ,nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. ,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion ,in combination with appropriate antibiotics for: ,? healing of duodenal ulcer associated with helicobacter pylori ,? eradication of helicobacter pylori in patients with active or healed peptic ulcer

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate, quantity: 43.5 mg - tablet, enteric coated - excipient ingredients: purified water; crospovidone; calcium hydrogen phosphate dihydrate; hypromellose; microcrystalline cellulose; self-emulsifying glyceryl monostearate; purified talc; polysorbate 80; hyprolose; sodium lauryl sulfate; triethyl citrate; methacrylic acid - ethyl acrylate copolymer (1:1); colloidal anhydrous silica; mannitol; magnesium stearate; propylene glycol; titanium dioxide; maltodextrin; iron oxide yellow; iron oxide red; polydextrose; medium chain triglycerides - gastro-oesophageal reflux disease (gord) ,? treatment of erosive reflux oesophagitis ,? long-term management of patients with healed oesophagitis to prevent relapse ,? symptomatic treatment of gastro-oesophageal reflux disease (gord) ,? patients requiring nsaid therapy ,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ,? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug ,nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. ,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion ,in combination with appropriate antibiotics for: ,? healing of duodenal ulcer associated with helicobacter pylori ,? eradication of helicobacter pylori in patients with active or healed peptic ulcer

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

mcneil products ltd - nicotine cyclodextrin complex - sublingual tablet - 2mg

美国 - 英文 - NLM (National Library of Medicine)

goldeneye permanent system gmbh germany - bambusa arundinacea stem extract (10%), maltodextrin (2.98%), aloe barbadensis leaf juice (0.5%), caffeine (0.2%) - skin exfoliate for enzymatic and mechanical facial skin peeling. keep skin soft and smooth.